Close
0
Inquiry Basket
Hot Products

GlycoErase™ GALNT14 Knockout Glycoengineered Cell

CAT#: GLJF-0825-JF239

Datasheet Request COA
Overview
Description
GlycoErase™ GALNT14 knockout glycoengineered cell eliminates GALNT14, a Golgi GalNAc-transferase that initiates mucin-type O-glycosylation. This model supports studies of mucin biosynthesis, signaling, and cancer biology.
Product Type
KO Cell Lines
Cell Line
As requested by the client.
Specification
Cell Viability
>90%
Sterility Test
The sterility test indicated an absence of microbial growth.
Identity Test
STR identification
Mycoplasma Test
Negative
Virus Test
Negative for HIV, HBV and HCV.
Genetic Stability Testing
We conduct cell genetic stability studies in full compliance with ICH guidelines. Our expertise enables us to design and execute a comprehensive testing program tailored to your specific needs and regulatory requirements.
Validation
PCR, Sanger Sequencing
Application
Functional assay
Size
1 M cells/vial*2
Product Format
Frozen
Shipping
Dry ice
Availability Status
Made to order
Handling Notes
Upon receipt, this product must be immediately transferred from dry ice to liquid nitrogen (-150°C to -190°C) and stored in a liquid nitrogen tank. Cell viability is critically dependent on proper handling. We cannot guarantee viability if these instructions are not strictly adhered to.
Product Disclaimer
This product is provided for research only, not suitable for human or animal use. Due to the inherent limitations of infectious agent testing, investigators must exercise extreme caution when handling cells provided by Creative Biolabs, treating all cells as potentially biohazardous.
Target Information
Target
GALNT14
Full Name
Polypeptide N-acetylgalactosaminyltransferase 14
Alternative Name
FLJ12691; GalNac-T14
Location
2p23.1
Gene ID
Summary
Golgi protein that catalyzes the transfer of GalNAc to hydroxyl groups of serines and threonines in target peptides, initiating O-linked glycosylation.
For Research Use Only.
Online Inquiry
Copyright © Creative Biolabs. All Rights Reserved.